Evidence map›Paper›PMID 36128847›Full record

ArticleChemMedChem2023

Optimization of N-Piperidinyl-Benzimidazolone Derivatives as Potent and Selective Inhibitors of 8-Oxo-Guanine DNA Glycosylase 1.

Olov Wallner, Armando Cázares-Körner, Emma Rose Scaletti, Geoffrey Masuyer, Tove Bekkhus, Torkild Visnes, Kirill Mamonov, Florian Ortis, Thomas Lundbäck, Maria Volkova and 13 more

Open access · hybridAbstract read
In one paragraph

Article in ChemMedChem, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. 8-Oxoguanine: A Lesion, an Epigenetic Mark, or a Molecular Signal?International journal of molecular sciences · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 4 countries.

Olov WallnerScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Armando Cázares-KörnerScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Emma Rose ScalettiDepartment of Biochemistry and Biophysics, Stockholm University, 10691, Stockholm, Sweden.
Geoffrey MasuyerDepartment of Biochemistry and Biophysics, Stockholm University, 10691, Stockholm, Sweden.
Tove BekkhusScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Torkild VisnesScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Kirill MamonovScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Florian OrtisScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Thomas LundbäckChemical Biology Consortium Sweden (CBCS), Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77, Stockholm, Sweden.
Maria VolkovaScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Tobias KoolmeisterScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Elisée WiitaScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Olga LosevaScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Monica PandeyScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Evert HomanScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Carlos Benítez-BuelgaScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Jonathan DaviesDepartment of Biochemistry and Biophysics, Stockholm University, 10691, Stockholm, Sweden.
Martin ScobieScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Ulrika Warpman BerglundScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Christina KalderénScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Pål StenmarkDepartment of Biochemistry and Biophysics, Stockholm University, 10691, Stockholm, Sweden.
Thomas HelledayScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Maurice MichelScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.ORCID 0000-0003-3261-2493
Science for Life Laboratory · SEStockholm University · SESINTEF · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

8-oxo Guanine DNA Glycosylase 1 is the initiating enzyme within base excision repair and removes oxidized guanines from damaged DNA. Since unrepaired 8-oxoG could lead to G : C→T : A transversion, base removal is of utmost importance for cells to ensure genomic integrity. For cells with elevated levels of reactive oxygen species this dependency is further increased. In the past we and others have validated OGG1 as a target for inhibitors to treat cancer and inflammation. Here, we present the optimization campaign that led to the broadly used tool compound TH5487. Based on results from a small molecule screening campaign, we performed hit to lead expansion and arrived at potent and selective substituted N-piperidinyl-benzimidazolones. Using X-ray crystallography data, we describe the surprising binding mode of the most potent member of the class, TH8535. Here, the N-Piperidinyl-linker adopts a chair instead of a boat conformation which was found for weaker analogues. We further demonstrate cellular target engagement and efficacy of TH8535 against a number of cancer cell lines.

Indexed as

DNA GlycosylasesNeoplasmsBenzimidazolesDNA DamageDNA RepairGuanineHumansBenzimidazolesbenzimidazoloneDNA GlycosylasesGuanine8-oxo guanine DNA glycoslyase 1Base excision repairInhibitorsOGG1TH5487

Identifiers

PMID36128847
PMCPMC10092094
OpenAlexW4296900401

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.